- Cassava Sciences press release (NASDAQ:SAVA): Q1 GAAP EPS of -$0.48.
- At March 31, 2025, cash and cash equivalents were $117.3 million, with no debt. .
More on Cassava Sciences
- Cassava Sciences: Downside From Alzheimer’s Results Still Possible Despite New Developments
- Cassava: Low-Cost Pivot Into TSC Epilepsy Is Unlikely To Create Long-Term Value
- 4 stocks to watch on Tuesday: GME, TSLA, SAVA and CCI
- Cassava to phase out Alzheimer’s program by Q2
- Seeking Alpha’s Quant Rating on Cassava Sciences